Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Providing Stability To The Vinyl Film Market

On August 2nd, Donald Trump announced tariffs on $16 billion worth of Chinese imports.  This was in addition to July’s announcement of tariffs on $34 billion worth of Chinese imports.  The 25% tariffs on the second tranche of goods went into effect on August 23rd. Creating Economic Uncertainty Among the goods being affected by this tariff is vinyl…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

On August 2nd, Donald Trump announced tariffs on $16 billion worth of Chinese imports. This was in addition to July’s announcement of tariffs on $34 billion worth of Chinese imports. The 25% tariffs on the second tranche of goods went into effect on August 23rd.

Creating Economic Uncertainty

Among the goods being affected by this tariff is vinyl film—a critical component in thousands of products including laminate flooring, awning, tents, medical fluid bags, etc. Manufacturers of these products can only pass on so much of the increased costs to their customers. These companies will have to cut corners elsewhere.

For manufacturers utilizing vinyl film, this tariff has caused much speculation and sector uncertainty. When uncertainty exists in any market, it’s not uncommon for industry stakeholders to take on a wait-and-see attitude. Current production will likely continue, but industry expansion will likely be put on hold until everyone has a better understanding of the actual consequences on pricing and supply.

Those companies who already source most of their vinyl film from U.S. companies will face the least uncertainty within their industries. This is something to keep in mind when considering your next move. When you source vinyl film from U.S. producers like Presco, you remove much of the uncertainty being generated by the new tariffs.

The Presco Advantage

Based in Sherman, Texas, Presco is America’s premier manufacturer of safety marking products and custom engineered vinyl film. Presco’s subsidiary, Pres-Flex, compounds and extrudes flexible vinyl film in Sherman, Texas. By sourcing engineered vinyl film from Presco/Pres-Flex, businesses can minimize costs while filling gaps the tariffs may create in supply chains. Additionally, products made in the U.S. provide many benefits sourcing overseas doesn’t, including better traceability of materials moving through the supply chain, a reduction or complete elimination of quality issues, and ensures quick responses to any bad material situations. Further, higher-quality American-made vinyl film will also result in higher-quality manufactured end-products.

If you find your operations facing a disruption in its vinyl film supply because of the newly imposed tariffs on Chinese goods, Presco/Pres-Flex is here to help!

To learn more about how Pres-Flex can help you with your vinyl film needs, visit them at www.pres-flex.com today!

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512